Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine whether glatiramer acetate (Copaxone) will induce anti-inflammatory type II monocyte development during treatment of MS, and if these antigen presenting cells...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
University of California, San Francisco
Collaborators
NCT07325292 · Multiple Sclerosis
NCT05748015 · Multiple Sclerosis
NCT06433765 · Multiple Sclerosis
NCT04876339 · Parkinson Disease, Stroke, and more
NCT07466823 · Multiple Sclerosis, Spasticity, and more
UCSF Multiple Sclerosis Center
San Francisco, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions